CagriSema is a once-weekly injection of semaglutide and cagrilintide. Clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a ...

Microdosing is the off-label use of GLP-1 receptor agonists at doses lower than those approved for the treatment of diabetes or obesity. There are numerous reasons people may explore microdosing, ...

This educational article was made possible with materials and support from Tandem Diabetes Care. Automated insulin delivery (AID) systems have been traditionally used by people with type 1 diabetes ...

Because GLP-1 receptor agonists slow down digestion, they may delay the absorption of oral medications like birth control pills, which could affect ovulation and fertility. As more people begin taking ...

Many important molecules in the body are peptides. Some peptides, like GLP-1, can be modified into effective medications for a variety of conditions, including diabetes. Recently, health, wellness, ...

Many people with diabetes struggle to manage mealtime blood sugar levels, even with new advances in technology. In a clinical trial of adults with type 1 diabetes, the inhaled insulin Afrezza ...

Here are some of the top technology highlights covered at the American Diabetes Association's 2026 scientific conference in New Orleans. Broadening access to diabetes technology and developing new ...

Off-label use of medications like Ozempic, Wegovy, Mounjaro, and Zepbound is becoming increasingly common to address weight management, insulin resistance, and diabetes related complications in type 1 ...

Unlike FDA-approved GLP-1 medications like Ozempic and Wegovy, dietary supplements like Lemme GLP-1 Daily do not require FDA approval or any data to support their marketing claims. Limited research ...

Tandem’s much-awaited Mobi automated insulin delivery system is available in the U.S. The Tandem Mobi is the world’s smallest insulin delivery system to be fully controllable by a smartphone. Now with ...

GLP-1-based medications have revolutionized blood sugar and weight management, but they aren’t effective for everyone. Eli Lilly, which makes the GLP-1/GIP drug Mounjaro (tirzepatide), is currently ...

The American Diabetes Association (ADA) recently released their 2025 Standards of Care, which – for the first time – includes recommendations for CGM use in type 2 diabetes, the use of GLP-1 drugs for ...